Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026

SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.

CHEST 2026 Presentation Details * Presentation Title: Efficacy of 52-Week Cytisinicline Treatment for Cigarette Smoking and E-Cigarette Cessation: The Open-Label ORCA-OL Trial * Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope * Date/Time: Tuesday, October 20, 2026, 2:09–2:13 p.m. MST * Presenter: Mark Rubinstein, MD, Chief Medical Officer, Achieve Life Sciences * Authors: Judith J. Prochaska, PhD, MPH, Stanford University; Neal L. Benowitz, MD, University of California, San Francisco; Dorothy K. Hatsukami, PhD, Masonic Cancer Center, University of Minnesota; Matthew E. Linley-Adams, Achieve Life Sciences; Mark L. Rubinstein, MD, Achieve Life Sciences; Nancy A. Rigotti, MD, Harvard Medical School The presentation will feature results from ORCA-OL, an open-label study that enrolled 475 adults who previously participated in the ORCA-2, ORCA-3 or ORCA-V1 trials and were actively smoking cigarettes and/or vaping daily. Participants received cytisinicline 3 mg three times daily for 52 weeks with behavioral support. The analysis evaluated abstinence throughout the 52-week treatment period, including biochemically verified four-week sustained abstinence and seven-day point prevalence abstinence.